Pegvorhyaluronidase alfa added to therapy,
does it really help with Improved overall survival in untreated stage IV hyaluronan-high pancreatic ductal adenocarcinoma?
research showsGrade D. In HALO 109-301, median overall survival was 11.2 versus 11.5 months, HR 1.00 (95% CI 0.80 to 1.27; P=.97). Objective response of 47% versus 36% was lower in the fixed testing hierarchy and could be confirmatory only if overall survival was significant first.
ads claimA 47% response rate must not be presented as longer survival. Both overall and progression-free survival were null.
Useful facts when choosing a product
- Both groups received nab-paclitaxel plus gemcitabine.
- Mandatory enoxaparin prophylaxis was used in both groups because of thromboembolic risk.
- Grade 3 or worse fatigue was 16.0% versus 9.6%, muscle spasms 6.5% versus 0.6%, and hyponatremia 8.0% versus 3.8%.
What the research actually shows
HALO 109-301 randomized 494 previously untreated stage IV pancreatic ductal adenocarcinoma patients with stromal hyaluronan staining of at least 50% in a 2:1 ratio and analyzed 492 by intention to treat. Halozyme Therapeutics sponsored and supported the trial and provided the protocol, study drug, placebo, and management. Two authors were company employees, and Halozyme paid Paragon for medical writing. Axis 6 B0 evidence ① Allocation concealment: patients were randomized 2:1 through a central interactive response system. ② Masking: this was a "randomized, double-blind, placebo-controlled" trial using matching placebo. ③ Analysis and missingness: 492 of 494 randomized patients were included in the "intent-to-treat population". ④ Prespecified primary endpoint: "The primary end point was overall survival" — consistent with the prespecified 2019 amendment to NCT02715804
Why this is classified as D (34)
The primary overall-survival endpoint was null in a large double-blind hard-outcome trial, giving D with 34 points. The interval retained possible benefit and the confirmed efficacy trial was manufacturer sponsored.
Counterpoint. Higher objective response is real but was not confirmatory under the fixed hierarchy and is not equivalent to survival benefit.
Rejudgment record. Cross-check applied — HALO 109-301's prespecified amended sole primary overall-survival endpoint and fixed testing hierarchy
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved overall survival | D | The result was null, HR 1.00, P=.97. |
| Increased objective response | C | It was 47% versus 36% but did not reach confirmatory testing under the fixed hierarchy. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Multicenter randomized double-blind placebo-controlled phase 3 trial | 1 | Halozyme Therapeutics sponsorship, support, drug, placebo, protocol, management, and writing costs | Primary overall survival | Median OS 11.2 vs 11.5 months; HR 1.00 (95% CI 0.80-1.27), P=.97; 330 deaths | Pivotal large null hard-outcome evidence |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] No Benefit of Pegvorhyaluronidase Alfa for Overall Survival in Hyaluronan-High Metastatic Pancreatic Adenocarcinoma — Evidence Grade D·34. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/pegvorhyaluronidase-alfa-hyaluronan-high-metastatic-pancreatic-cancer-overall-survival/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.